Cyclin E1 regulates the initiation of S-phase in cellular division. However, in many cancers, cyclin E1 is aberrantly overexpressed and this molecular phenotype correlates with increased tumor aggressiveness and poor patient survival. The molecular cause(s) of cyclin E1 abnormalities in cancers is poorly understood.
Introduction
Cyclin E1, an activator of cyclin-dependent kinase 2 (Cdk2), is an important regulator of the G 1 -S-phase transition of the cell division cycle. Cyclin E1 initiates an S-phase program by promoting histone biosynthesis, centrosome duplication, and licensing of DNA origins of replication, among other functions (1) . Cyclin E1 protein level is tightly regulated during cellular division through coordinated transcriptional and proteolytic controls, which ensure its expression is restricted to the G 1 -Sphase transition. CCNE1, which encodes cyclin E1, is expressed in late G 1 phase stimulated by E2F and c-Myc activities through Cdk2-dependent positive feedback loops (1) . Once S-phase is initiated, cyclin E1 is targeted for ubiquitin-dependent proteolysis by the E3 ubiquitin ligase SCF Fbxw7 (2, 3) . Ubiquitylation of cyclin E1 is triggered by phosphorylation of residues Thr395, Ser399, and to a lesser extent Thr77, mediated by autophosphorylation and GSK3 kinase, creating N-and C-terminal phosphodegrons (also termed CPD) that promote its recognition by SCF Fbxw7 (4) .
A wealth of clinical studies have shown that cyclin E1 is aberrantly overexpressed in many human cancers and this molecular phenotype often correlates with increased tumor aggressiveness and poor patient survival. For example, approximately 30% of breast cancers overexpress cyclin E1 and this molecular abnormality has been shown to be a stronger prognostic marker of poor patient outcome than important clinicopathologic factors such as tumor grade/stage, hormone receptor status, or lymph node metastasis (5) . Cyclin E1 overexpression is also a major molecular determinant of basal-like triple negative breast cancers [TNBC; estrogen receptor (ER À ), progesterone receptor (PR À ), and Her2 À ], a highly aggressive breast cancer subtype that is common in BRCA1 mutation carriers, and is an independent predictor of poor patient outcome (6) . Cyclin E1 overexpression has also been associated with increased resistance to the anti-Her2 therapy trastuzumab in breast cancers (7) . At the molecular level, cyclin E1 overexpression alters gene expression programs that regulate cellular division, differentiation, survival, and senescence (1) . It has also been shown to promote genetic instability by causing defects in chromosome segregation (8) (9) (10) , centrosome hyperamplification (11) , interference with the prereplication complex assembly (12) , and formation of unstable DNA replication intermediates (13, 14) .
Despite the importance of cyclin E1 in cancer, the molecular mechanisms that promote its dysregulation are poorly understood. In breast cancers, genetic amplifications of CCNE1 occur in only approximately 5% of cases (15) . Furthermore, mutations of FBXW7, which encodes the substrate recognition component of SCF Fbxw7 , are exceedingly rare (<1%; ref. 16) . Therefore, other molecular mechanisms must be responsible for cyclin E1 overexpression in these cancers, which allow for its hyperaccumulation in the presence of functional degradation machinery.
Materials and Methods

Patient specimens and cell lines
Breast cancer specimens were obtained from patients treated at the Department of Obstetrics and Gynecology of the Innsbruck Medical University in Austria using Institutional Review Board-approved procedures. Clinicopathologic information for tumor specimens is provided in Supplementary  Table S1 . Cell lines were purchased from the American Tissue Culture Collection and grown in the recommended culture mediums. Detailed information about tumor analysis, cell line treatments, and plasmid and siRNAs transfections is provided in Supplementary Material and Methods.
Ubiquitylation assays
In vivo ubiquitylation assays were performed by cotransfecting HEK293T cells with the indicated expression plasmids and siRNAs and 48 hours later treating cells with 10 mmol/L MG132 for 4 hours before harvesting. Cells were lysed using denaturing conditions (1% SDS) as described (17) . The Thr77Ala/ Thr395Ala mutant of cyclin E1 was created using the Quikchange Site-Directed Mutagenesis Kit (Agilent). In vitro ubiquitylation reactions were performed as described previously (18) . Human recombinant SCF Fbxw7 was generated by multi-infecting Sf9 insect cells with the relevant expressing baculoviruses. Recombinant cyclin E1-Cdk2 was purchased from EMD Millipore.
Cell fractionation
Cells were suspended in buffer containing 10 mmol/L Tris (pH 7.4), 5 mmol/L MgCl 2 , 10 mmol/L KCl, 300 mmol/L sucrose, 0.1 mmol/L EDTA, 0.5 mmol/L dithiothreitol, with added phosphatase and protease inhibitors and incubated on ice for 10 minutes. NP-40 was then added to a final concentration of 0.125%, the cells vortexed for 10 seconds, and the cytoplasmic fraction clarified by centrifugation at 1,000 rpm in a microfuge. The nuclear pellet was then washed 4Â in buffer containing 10 mmol/L Hepes (pH 7.4), 50 mmol/L NaCl, 25% glycerol, and 0.1 mmol/L EDTA, with the last wash spun at 6,000 rpm in a microfuge. The nuclear fraction was then isolated by incubation in buffer containing 20 mmol/L Tris (pH 7.4), 5 mmol/L MgCl 2 , 300 mmol/L KCl, 0.2 mmol/L EDTA, 0.5 mmol/L dithiothreitol, and 25% glycerol, with phosphatase and protease inhibitors for 15 minutes, and the lysate clarified by centrifugation at 13,000 rpm for 15 minutes.
Phosphatase and kinase assays
For phosphatase assays, human recombinant cyclin E1-Cdk2 was incubated with PP2A core enzyme (EMD Millipore) in phosphatase reaction buffer (12.5 mmol/L Tris (pH 7.0), 25 mmol/L CaCl 2 ) for 30 minutes at 30 C. Okadaic acid (EMD Millipore) and lPPase (New England Biolabs) were added to the indicated reactions. For PP2A-B55b phosphatase assays, PP2A-B55b complexes were assembled in HEK293T cells, immunopurified, and reactions performed as described above using recombinant cyclin E1-Cdk2 as substrate. Anti-Flag antibodies were purchased from Sigma-Aldrich. Kinase assays were performed by incubating human recombinant pRb with cyclin E1 immunoprecipitated from cell extracts (250 mg) with antibody HE172. Reactions were performed at 30 C for 30 minutes in reaction buffer containing 20 mmol/L Tris (pH 7.5), 7.5 mmol/L MgCl 2 , and g-32 p-ATP.
Mouse tumor studies
MDA-MB-231-luc-D3H2LN cells were transduced with control or B55b short hairpin RNA (shRNA)-expressing lentiviruses, combined with Matrigel (BD Biosciences), and 2 Â 10 6 cells injected into the mammary fat pads of 4-to 6-week-old female beige nude mice. Twelve mice were injected for each group. Tumor growth and metastasis were monitored using a Xenogen IVIS 200 Imaging System.
Statistical analysis
Linear and nonlinear regression analyses were used to evaluate potential correlations between expression of PP2A b-subunits, Fbxw7a, and CCNE1 and cyclin E1 protein levels in breast tumors and differences in cell and tumor growth rates, respectively. A P value <0.05 was considered statistically significant. All calculations were performed using GraphPad Prizm 5 software (GraphPad Software Inc.).
Results
PP2A dephosphorylates cyclin E1 and protects it from ubiquitylation by SCF Fbxw7
Because cyclin E1 degradation is triggered by Cdk2 and GSK3 phosphorylations, we explored whether cyclin E1 overexpression in cancers could possibly be caused by dysregulation of a protein phosphatase that counteracted these activities. Cyclin E1 and components of protein phosphatase 2A (PP2A) were previously identified in immunocomplexes of DNA polymerase a-primase (19) . Interestingly, PP2A had been previously shown to regulate the phosphorylation status and degradation of c-Myc, another SCF Fbxw7 substrate (20, 21) . PP2A is a Ser/Thr phosphatase, which plays important roles in cell division control and cancer. We confirmed that both expressed and endogenous cyclin E1 interacted with the Aa (structural) and Ca (catalytic) subunits of PP2A by immunoprecipitation (IP)-Western blot analysis ( Fig. 1A and B ). Incubation of recombinant cyclin E1-Cdk2 complexes with recombinant PP2A core enzyme showed that PP2A could dephosphorylate both the N-and C-terminal phosphodegrons of cyclin E1 (Fig. 1C ). In support of this in vitro result, knockdown of Ca subunit expression in HeLa cells by siRNA was found to induce significant increases in phosphorylation of both Thr77 and Thr395 of cyclin E1 (Fig. 1D ). These data suggested that PP2A might function to protect cyclin E1 from ubiquitylation by counteracting Cdk2-and GSK3-mediated phosphorylations. To test this, we coexpressed cyclin E1, Cdk2, Fbxw7a, and HAubiquitin in HEK293T cells and then knocked down Ca expression by siRNA. IP-Western blot analysis revealed that Ca knockdown significantly increased ubiquitylation of cyclin E1 in vivo ( Fig. 1E ). However, no increase in ubiquitylation was observed in similar experiments that used a mutant version of cyclin E1 that had both its phosphodegrons mutated (Thr77Ala/Thr395Ala), confirming the effect was mediated through cyclin E1 phosphorylation ( Fig. 1E ). Furthermore, addition of PP2A core enzyme to in vitro ubiquitylation reactions of cyclin E1 by SCF Fbxw7 was found to decrease the ubiquitylation efficiency ( Fig. 1F ). Collectively, these results indicated that PP2A counteracted cyclin E1 phosphorylations, thus protecting it from ubiquitylation by SCF Fbxw7 .
PP2A-B55b regulates cyclin E1 phosphorylation
PP2A exists as a dimeric core composed of A and C subunits bound to a regulatory (B) subunit, which dictates subcellular localization and substrate specificity (22) . Humans express 2-A, 2-C, and 16-B subunits, allowing for a diverse array of enzyme compositions, each with presumably a unique set of substrates.
Ectopic coexpression experiments revealed that cyclin E1 coprecipitated with several subunits of the B55 and B56 b-subunit families in vivo ( Fig. 2A ). Knockdown of expression of these b-subunits in HeLa cells showed that B55b and B56d, and to a lesser extent B56b, reduced cyclin E1 protein levels comparable with Ca knockdown (Fig. 2B ), as would be expected if their loss of function deprotected cyclin E1 from ubiquitin-dependent proteolysis. Several lines of evidence led us to exclude both B56b and B56d as potential regulators of cyclin E1. First, we could not verify an in vivo interaction between these b-subunits and endogenous cyclin E1 protein ( Supplementary Fig. S1 ). Second, quantitative PCR (qPCR) analysis failed to detect any correlation between B56b or B56d expression and cyclin E1 protein levels in breast cancer specimens (described below). Third, the expression of both B56b and B56d during the cell division cycle was not consistent with a potential role in cyclin E1 degradation, with both peaking in S-phase when cyclin E1 degradation is maximal (see Fig. 3B ). In addition, mass spectrometry analysis of B55b identified several b-subunits as potential interacting proteins, suggesting the observed interactions between B56b or B56d and cyclin E1 could be indirect (data not shown). We therefore focused on B55b, encoded by PPP2R2B, and its potential regulation of cyclin E1. Knockdown of B55b expression using three different siRNAs confirmed a reductive effect on cyclin E1 protein level, even though CCNE1 expression and cell cycle kinetics were not adversely affected ( Supplementary Figs. S2  and S3 ). B55b was found to coprecipitate with endogenous cyclin E1 protein (Fig. 2C) . Cell fractionation experiments also showed that B55b localized to both the cytoplasm and nucleus in HeLa cells, mirroring cyclin E1 (Fig. 2D ). This result was contrary to previous reports, which found that B55b is localized to the cytoplasm (23, 24) . In addition, treatment of cells with proteasome inhibitor MG132 or chemical inhibitors of Cdk2 and GSK3 kinases was found to diminish the reduction in cyclin E1 caused by B55b knockdown, confirming that the effect of B55b on cyclin E1 was both proteasome-and phosphorylation-dependent ( Fig. 2E and F) . Moreover, PP2A-B55b complexes assembled in HEK293T cells were found to efficiently dephosphorylate both the N-and C-terminal phosphodegrons of recombinant cyclin E1 in vitro (Fig. 2G) . Collectively, these data demonstrated that PP2A-B55b selectively targets the N-and C-terminal phosphodegrons of cyclin E1 for dephosphorylation.
PP2A-B55b regulates cyclin E1 stability and determines its level in cell division cycles and cancer-derived cell lines
We next evaluated the potential importance of PP2A-B55b in determining cyclin E1 levels in cellular division and cancer. Cyclohexamide half-life determination experiments showed that B55b expression significantly increased the stability of cyclin E1 expressed in HEK293T cells (20 vs. >90 minutes; HeLa cells were transfected with a plasmid that expresses Flag-B55b and cytoplasmic and nuclear fractions isolated. Exclusive nuclear protein PARP is shown as verification of fractionation efficiency. E, B55b knockdown-induced decrease of cyclin E1 in HeLa cells is proteasome-dependent. B55b expression was knocked down for 48 hours and proteasome inhibitor MG132 added 4 hours before harvesting cells. F, B55b knockdown-induced decrease of cyclin E1 is phosphorylation-dependent. Cells were treated with Cdk2 and GSK3 inhibitors for 4 hours before harvesting. G, PP2A-B55b dephosphorylates cyclin E1 in vitro. PP2A-B55b complexes were assembled in HEK293T cells and used in in vitro phosphatase reactions with recombinant cyclin E1-Cdk2 as substrate. Fig. 3A) , consistent with its role in protecting cyclin E1 from ubiquitin-dependent proteolysis by SCF Fbxw7 . To determine whether B55b could play a role in the regulation of cyclin E1 in cell division cycles, we synchronized HeLa cells transfected with control or B55b siRNAs at the G 1 -S boundary and then analyzed cyclin E1 levels by Western blotting following release into the cell division cycle. Knockdown of B55b expression was found to reduce the accumulation of cyclin E1 at the G 1 -S boundary and this was accompanied by increased Thr395 phosphorylation, whereas cyclin A and B1 levels were unaffected ( Fig. 3B ). In addition, qPCR analysis revealed B55b expression mirrored cyclin E1 protein, peaking at the G 1 -S boundary and decreasing as cells progressed into S-phase ( Fig.  3B) . To examine the potential influence of B55b on cyclin E1 levels in cancer cells, we transfected MDA-MB-231 TNBC cells with plasmids that express Myc-cyclin E1 and all components required for its degradation (e.g., Fbxw7 and Cdk2), and then modulated B55b expression by siRNA or ectopic expression. Whereas B55b knockdown significantly reduced cyclin E1 protein level, its ectopic expression induced cyclin E1 hyperaccumulation (Fig. 3C) . These results suggested that cyclin E1 levels in cancer cells were largely determined by PP2A-B55b. To test this hypothesis, we quantified the levels of cyclin E1 protein and PPP2R2B and CCNE1 expression in breast cancer specimens by Western blotting and qPCR, respectively. Remarkably, cyclin E1 protein level was found to correlate more strongly with PPP2R2B expression than CCNE1 expres-sion (R 2 ¼ 0.41 vs. 0.14; Fig. 4A ), and this correlation was enhanced for breast cancers that expressed CCNE1 at !50% above the mean (R 2 ¼ 0.70 vs. 0.10; Fig. 4B ). Because cyclin E1 degradation is regulated by SCF Fbxw7 , we also analyzed its potential influence on determining cyclin E1 levels in breast cancers. qPCR analysis failed to uncover a significant correlation between cyclin E1 protein level and FBXW7a expression in these specimens ( Supplementary Fig. S4 ). Furthermore, our previous analysis showed that these same breast cancer specimens do not contain mutations of the FBXW7 gene, a potential mechanism of SCF Fbxw7 inactivation in cancers (16) . Of note, we also found no correlations between cyclin E1 protein levels and expression of B56b or B56d ( Supplementary Fig. S4) . Therefore, these data demonstrated that the level of cyclin E1 in cancer cells is largely determined by B55b.
PP2A-B55b inhibition reduces breast cancer cell growth in vitro and tumor formation in vivo
We next tested the potential therapeutic application of PP2A-B55b inhibition as a means of decreasing cyclin E1 levels in breast cancer cells. Knockdown of B55b expression in a panel of breast cancer cell lines representing both luminal hormone receptor-positive (ER þ , PR þ ; MCF-7, and T47-D) and basal-like TNBCs (ER À , PR À , Her2 À ; BT-549, MDA-MB-231, MDA-MB-468, MDA-MB-157, MDA-MB-436, and SUM149PT) was found to decrease cyclin E1 protein levels in all cell lines except SUM149PT (Fig. 4C) , which has been shown to harbor Figure 3 . B55b regulates cyclin E1 stability and determines its level in cell lines and cell division cycles. A, B55b stabilizes cyclin E1. HEK293T cells were cotransfected with plasmids that express Myc-cyclin E1, Cdk2, Flag-Fbxw7a, and Flag-B55b or empty vector; protein synthesis was halted by cyclohexamide (CHX) treatment and Myc-cyclin E1 stability analyzed by immunoblotting. B, B55b is required for proper accumulation of cyclin E1 at the G1-S transition. HeLa cells were transfected with control or B55b siRNA, the cell cycle blocked at the G1-S boundary, and then released from block and cell cycle proteins were analyzed by immunoblotting. qPCR data for expression of B55b, B56b, and B56d are shown below. C, B55b determines cyclin E1 levels in MDA-MB-231 breast cancer cells.
FBXW7 gene mutations (25) . Of note, B55b knockdown even reduced cyclin E1 levels in MDA-MB-157 cells, which contain a CCNE1 gene amplification and overexpress cyclin E1 at 64-fold the level of normal breast epithelial cells (26) . B55b expression knockdown also resulted in reduced cyclin E1-Cdk2-associated kinase activity (Fig. 4D) . To evaluate the effects of B55b expression knockdown on breast cancer cell growth, we tranduced two basal-like TNBC cell lines (MDA-MB-231 and MDA-MB-157) with B55b shRNA-expressing or control lentiviruses.
B55b knockdown was found to significantly reduce long-term cell proliferation (Fig. 4E) . Moreover, MDA-MB-231-luc cells transduced with B55b shRNA-expressing lentiviruses displayed a significantly reduced growth rate and ability to form tumors when implanted into the mammary fat pads of nude mice compared with control cells (Fig. 5A and B) . The B55b shRNA-expressing tumors also failed to metastasize to bronchial lymph nodes (0/12 vs. 2/12 for control tumors; Fig. 5C ), the preferred metastatic site for this model system. These 
Discussion
Although cyclin E1 overexpression is an important prognostic marker in breast and other cancers, the molecular cause(s) of these alterations was poorly understood. Our data show that the protein phosphatase PP2A-B55b regulates cyclin E1 levels in cellular division cycles and contributes to its dysregulation in cancers (Fig. 5D ). During G 1 phase, PP2A-B55b antagonizes phosphorylations of cyclin E1 mediated by autophosphorylation and GSK3 kinase, allowing for cyclin E1 to accumulate and initiate an S-phase program. After S-phase is initiated, B55b levels decline, which deprotects cyclin E1 from phosphoryla-tion, thus triggering its recognition and ubiquitylation by SCF Fbxw7 . In support of a possible involvement of PP2A in cyclin E1 regulation, a recent report found that in yeast PP2A Cdc55 controls the stability of G 1 cyclin Cln2 through regulation of its phosphorylation state (27) . In cancers, this regulation can be aberrant and augmented B55b expression functions to antagonize cyclin E1 degradation, leading to its hyperaccumulation especially in cells that overexpress CCNE1. The overexpressed cyclin E1 then promotes cancer cell survival, hormone-independent growth, genetic instability, and progression to advanced disease.
The ability of augmented B55b to promote cyclin E1 overexpression suggests that it could function as an oncoprotein in human tumorigenesis. Indeed, a search of the ONCOMINE database (28) revealed that PPP2R2B is overexpressed in several cancer types, including breast, ovary, brain, and liver ( Supplementary Fig. S5 ). However, a previous report showed that PPP2R2B is often transcriptionally repressed by promoter hypermethylation in colorectal cancers, suggesting it functions as a tumor suppressor in these cancers (29) . Contrary to this study though, we found that knockdown of B55b expression in colorectal cancer cell lines HT29 and HCT116, which contain hypermethylated PPP2R2B alleles, significantly reduced their proliferation and cyclin E1 levels ( Supplementary Fig. S6) . A possible explanation for this discrepancy could be that reduced B55b expression imparts tumorigenic properties on colorectal cancer cells that are independent of cyclin E1, though B55b expression is indispensable for proliferation. PP2A-B55b ablation reduced cyclin E1 protein levels in breast cancer cells that contain functional SCF Fbxw7 , suggesting its inhibition could represent a rational therapeutic strategy for inactivating cyclin E1 function in cancers. The oncogenic potential of cyclin E1 has been shown to be mediated through both Cdk2-dependent and -independent functions, the latter of which includes promotion of G 0 -S-phase transition and oncogene-mediated transformation (30) . Therefore, PP2A-B55b inhibition could represent a more effective therapeutic mechanism for abrogating cyclin E1 functions in cancers than drugs that target Cdk2 kinase activity, because both Cdk2-dependent and -independent functions would be affected. PP2A-B55b-directed therapies might be particularly effective for treatment of highly aggressive basal-like TNBCs, which typically overexpress cyclin E1, lack targeted and effective therapies, and whose growth and survival have been shown to depend on these abnormalities (31) . They might also be effective as a prophylactic treatment for carriers of BRCA1 mutations, who exhibit an increased risk of developing basallike TNBCs in their lifetime.
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